MGV354

• Description :

  MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of [1][2].

• UNSPSC :

  12352005

• Target :

  Guanylate Cyclase

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/sGC_activator_1.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C(C)N(C2=NC(C3=CC=CC4=C3[C@@H](NC5=CC=C(C6CCN(C(C7CC7)=O)CC6)C=C5C)CC4)=CC=C2)N=C1)O

• Molecular Formula :

  C35H37N5O3

• Molecular Weight :

  575.70

• References & Citations :

  [1]Ehara T, et al. The Discovery of (S) -1- (6- (3- ((4- (1- (Cyclopropanecarbonyl) piperidin-4-yl) -2-methylphenyl) amino) -2,3-dihydro-1 H-inden-4-yl) pyridin-2-yl) -5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma. J Med Chem. 2018 Mar 22;61 (6) :2552-2570.|[2]Stacy R, et al. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.Am J Ophthalmol. 2018 Aug;192:113-123.|[3]Prasanna G, et al. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.Invest Ophthalmol Vis Sci. 2018 Apr 1;59 (5) :1704-1716.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2